Welcome!

News Feed Item

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014

NEW YORK, March 18, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02051434/Diffuse-Large-B-Cell-Lymphoma-Global-Clinical-Trials-Review-H1-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Diffuse Large B-Cell Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diffuse Large B-Cell Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 6
Diffuse Large B-Cell Lymphoma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Diffuse Large B-Cell Lymphoma 25
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma 37
Dec 09, 2013: Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial 37
Aug 15, 2013: Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS in Combination with Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma 37
Jun 16, 2013: Pharmacyclics Announces Results Of Two Phase II Ibrutinib Studies In Patients With Mantle Cell Lymphoma Or Diffuse Large B-Cell Lymphoma 38
Jun 10, 2013: Immunomedics's 90Y-Epratuzumab Study Shows Improvement Of Therapy Results Following R-CHOP In Patients With Diffuse Large B-Cell Lymphoma 39
May 10, 2013: Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint In Diffuse Large B-Cell Lymphoma 40
Clinical Trial Profiles 41
Clinical Trial Overview of Top Companies 41
F. Hoffmann-La Roche Ltd. 41
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 41
Celgene Corporation 44
Clinical Trial Overview of Celgene Corporation 44
Amgen Inc. 46
Clinical Trial Overview of Amgen Inc. 46
Novartis AG 48
Clinical Trial Overview of Novartis AG 48
Takeda Pharmaceutical Company Limited 50
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 50
Pharmacyclics, Inc. 51
Clinical Trial Overview of Pharmacyclics, Inc. 51
GlaxoSmithKline plc 52
Clinical Trial Overview of GlaxoSmithKline plc 52
Bayer AG 53
Clinical Trial Overview of Bayer AG 53
AstraZeneca PLC 54
Clinical Trial Overview of AstraZeneca PLC 54
Immunomedics, Inc. 55
Clinical Trial Overview of Immunomedics, Inc. 55
Clinical Trial Overview of Top Institutes / Government 56
National Cancer Institute 56
Clinical Trial Overview of National Cancer Institute 56
Fred Hutchinson Cancer Research Center 61
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 61
Groupe d'Etudes de Lymphomes de L'Adulte 64
Clinical Trial Overview of Groupe d'Etudes de Lymphomes de L'Adulte 64
Mayo Clinic 65
Clinical Trial Overview of Mayo Clinic 65
The University of Texas M. D. Anderson Cancer Center 66
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 66
FUDAN University 67
Clinical Trial Overview of FUDAN University 67
Memorial Sloan Kettering Cancer Center 68
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 68
The Lymphoma Academic Research Organisation 69
Clinical Trial Overview of The Lymphoma Academic Research Organisation 69
Massachusetts General Hospital 70
Clinical Trial Overview of Massachusetts General Hospital 70
Stanford University 71
Clinical Trial Overview of Stanford University 71
Five Key Clinical Profiles 72
Appendix 164
Abbreviations 164
Definitions 164
Research Methodology 165
Secondary Research 165
About GlobalData 166
Contact Us 166
Disclaimer 166
Source 167

List of Tables

Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2014* 7
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 41
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 44
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 46
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 48
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 50
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014* 51
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 52
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 53
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 54
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Immunomedics, Inc., 2014* 55
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 56
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 61
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Groupe d'Etudes de Lymphomes de L'Adulte, 2014* 64
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014* 65
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 66
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014* 67
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 68
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The Lymphoma Academic Research Organisation, 2014* 69
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 70
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 71

List of Figures
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 165

To order this report: Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02051434/Diffuse-Large-B-Cell-Lymphoma-Global-Clinical-Trials-Review-H1-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, will discuss the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filte...
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies adopt disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advanced analytics, and DevO...
Fortunately, meaningful and tangible business cases for IoT are plentiful in a broad array of industries and vertical markets. These range from simple warranty cost reduction for capital intensive assets, to minimizing downtime for vital business tools, to creating feedback loops improving product design, to improving and enhancing enterprise customer experiences. All of these business cases, which will be briefly explored in this session, hinge on cost effectively extracting relevant data from ...
SYS-CON Events announced today that VAI, a leading ERP software provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. VAI (Vormittag Associates, Inc.) is a leading independent mid-market ERP software developer renowned for its flexible solutions and ability to automate critical business functions for the distribution, manufacturing, specialty retail and service sectors. An IBM Premier Business Part...
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed...
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
In most cases, it is convenient to have some human interaction with a web (micro-)service, no matter how small it is. A traditional approach would be to create an HTTP interface, where user requests will be dispatched and HTML/CSS pages must be served. This approach is indeed very traditional for a web site, but not really convenient for a web service, which is not intended to be good looking, 24x7 up and running and UX-optimized. Instead, talking to a web service in a chat-bot mode would be muc...
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 ad...
Advances in technology and ubiquitous connectivity have made the utilization of a dispersed workforce more common. Whether that remote team is located across the street or country, management styles/ approaches will have to be adjusted to accommodate this new dynamic. In his session at 17th Cloud Expo, Sagi Brody, Chief Technology Officer at Webair Internet Development Inc., focused on the challenges of managing remote teams, providing real-world examples that demonstrate what works and what do...
As enterprises work to take advantage of Big Data technologies, they frequently become distracted by product-level decisions. In most new Big Data builds this approach is completely counter-productive: it presupposes tools that may not be a fit for development teams, forces IT to take on the burden of evaluating and maintaining unfamiliar technology, and represents a major up-front expense. In his session at @BigDataExpo at @ThingsExpo, Andrew Warfield, CTO and Co-Founder of Coho Data, will dis...
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management...
SYS-CON Events announced today that AppNeta, the leader in performance insight for business-critical web applications, will exhibit and present at SYS-CON's @DevOpsSummit at Cloud Expo New York, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. AppNeta is the only application performance monitoring (APM) company to provide solutions for all applications – applications you develop internally, business-critical SaaS applications you use and the networks that deli...
It's easy to assume that your app will run on a fast and reliable network. The reality for your app's users, though, is often a slow, unreliable network with spotty coverage. What happens when the network doesn't work, or when the device is in airplane mode? You get unhappy, frustrated users. An offline-first app is an app that works, without error, when there is no network connection.